Detalhe da pesquisa
1.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
2.
Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.
Haematologica
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235519
3.
2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis.
Heart Lung Circ
; 33(4): 420-442, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38570258
4.
Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.
Acta Haematol
; 146(2): 166-171, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273464
5.
Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma.
Intern Med J
; 53(8): 1469-1477, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37093163
6.
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.
Intern Med J
; 53(5): 819-824, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36880355
7.
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
Br J Haematol
; 198(6): 988-993, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608261
8.
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Br J Haematol
; 198(5): 830-837, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35818641
9.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
10.
Current approaches to the diagnosis and management of amyloidosis.
Intern Med J
; 52(12): 2046-2067, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36478370
11.
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia.
Intern Med J
; 51(10): 1707-1712, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34664367
12.
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
Med J Aust
; 212(10): 481-489, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32401360
13.
Bortezomib use and outcomes for the treatment of multiple myeloma.
Intern Med J
; 50(9): 1059-1066, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32369254
14.
Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices.
Intern Med J
; 50(12): 1475-1482, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043739
15.
The epidemiology of amyloidosis in Queensland, Australia.
Br J Haematol
; 186(6): 829-836, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31148162
16.
The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population.
Br J Haematol
; 200(2): e17-e21, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36321478
17.
Relative survival of patients with lymphoma in Queensland according to histological subtype.
Med J Aust
; 209(4): 166-172, 2018 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30092750
18.
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Intern Med J
; 48(2): 210-220, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29415351
19.
The treatment of paraprotein-related kidney disease.
Curr Opin Nephrol Hypertens
; 26(6): 477-483, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28885307
20.
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Haematologica
; 107(1): 321-325, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34587718